Denis Gravel
Direktor/Vorstandsmitglied bei Transdiff, Inc.
Profil
Denis Gravel is the founder of Enobia Pharma, Inc. which was founded in 1997.
Currently, he holds the position of Director at Transdiff, Inc. and Centre de Transmission J.D.H., Inc.
Aktive Positionen von Denis Gravel
| Unternehmen | Position | Beginn |
|---|---|---|
Transdiff, Inc.
 Transdiff, Inc. Specialty StoresRetail Trade Transdiff, Inc. provides truck dealership services. Its services include transmission, differential, engine, drive shaft, parts, mechanical service, and sale of new and used trucks. The company is headquartered in Quebec, Canada. | Direktor/Vorstandsmitglied | - |
Centre de Transmission J.D.H., Inc.
 Centre de Transmission J.D.H., Inc. Wholesale DistributorsDistribution Services Centre de Transmission J.D.H., Inc. engages in the sale of new trucks and Peterbilt parts and services. The company was founded in 1976 and is headquartered in Quebec, Canada. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Denis Gravel
| Unternehmen | Position | Ende |
|---|---|---|
Enobia Pharma, Inc.
 Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Gründer | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Health Technology |
Transdiff, Inc.
Transdiff, Inc. Specialty StoresRetail Trade Transdiff, Inc. provides truck dealership services. Its services include transmission, differential, engine, drive shaft, parts, mechanical service, and sale of new and used trucks. The company is headquartered in Quebec, Canada. | Retail Trade |
Centre de Transmission J.D.H., Inc.
Centre de Transmission J.D.H., Inc. Wholesale DistributorsDistribution Services Centre de Transmission J.D.H., Inc. engages in the sale of new trucks and Peterbilt parts and services. The company was founded in 1976 and is headquartered in Quebec, Canada. | Distribution Services |
